Bracket Acquires Clintara In Move To Strengthen Rater Training, Quality Assurance, And Electronic Clinical Outcomes Assessment Capabilities
Bracket brings proven industry leadership and expertise with the addition of Dr. Steven Targum
(WAYNE, Pennsylvania and BOSTON) – Bracket Global, LLC and Clintara are pleased to announce the two companies have agreed to combine. Bracket will integrate the Clintara platform of surveillance strategies developed for clinical trials within Bracket’s proprietary electronic platform for Clinical Outcome Assessments (eCOA). The integration will include Clintara’s innovative C-VISA Subject Eligibility Validation program designed to ensure appropriate patients are enrolled in clinical trials.
Bracket CEO Jeff Kinell stated, “I am impressed by the culture, business practices, and scientific innovation reflected in Clintara’s steady growth and impact on our industry. I am truly excited about our future opportunities together.”
Founded in 2009 by Steven D. Targum, MD, Clintara’s methodology and technology includes audio-digital pen recordings of site-based interviews and site-independent “dual” scoring reviews. The Clintara surveillance strategy has enhanced ratings precision and improved the data integrity of clinical trials.
The Clintara leadership will assume expanded roles within Bracket. Dr. Targum will become the Scientific Director of Bracket and will work closely with Bracket’s Senior Vice President and Chief Medical Officer, David Daniel, MD. Clintara CEO Colin Bower will become Vice President, Scientific Services and will work with the Bracket leadership team and Scientific Advisory Board to develop cutting-edge solutions to improve the conduct of clinical trials.
Clintara is a privately-held clinical service and technology company headquartered in Boston, MA. Clintara was founded in 2009 by Dr. Steven Targum, MD. Clintara has conducted over 60 trials which have included 23,000 screens at over 2,200 sites around the world.
Bracket, with seven offices and more than 500 employees worldwide, is focused on bringing together best-in-class science, technology and service to drive superior clinical outcome results for pharmaceutical companies and for patients. In August 2013, Bracket became an independent portfolio company of Parthenon Capital Partners, a Boston- and San Francisco-based growth-oriented private equity firm that provides capital and strategic resources to growing middle market companies for acquisitions and internal growth.
For Immediate Release June 23, 2015
Contact: Adam Butler
+1 (610) 225-5900